Silver Book Fact

Antibiotic resistance of Klebsiella pneumoniae on the rise

Resistance of Klebsiella pneumoniae to antibiotics has dramatically increased- from 5.3% to 11.6% for third generation cephalosporins (between 1999 and 2010), and from <0.1% to 4.5% for carbapenams (between 2002 and 2010).

Braykov N, Eber M, Klein E, Morgan D, et al. Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol. 2013; 34(3): 259-68. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/div-classtitletrends-in-resistance-to-carbapenems-and-third-generation-cephalosporins-among-clinical-isolates-of-span-classitalicklebsiella-pneumoniaespan-in-the-united-states-19992010div/92079FCA7AE739268B12B1EA67759598

Reference

Title
Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010
Publication
Infect Control Hosp Epidemiol
Publication Date
2013
Authors
Braykov N, Eber M, Klein E, Morgan D, et al
Volume & Issue
Volume 34, Issue 3
Pages
259-68
URL
Read Full Resource

Categories

  • Cost of Disease
  • Prevalence & Incidence

Related Facts

  • Mortality rate from hospital-acquired pneumonia
    The mortality rate for hospital-acquired pneumonia ranges from 38% to more than 70%.  
  • Significant increase of penicillin-resistant Streptococcus penumoniae
    High-level penicillin-resistant Steptococcus pneumoniae increased 1,000-fold over 17 years.  
  • Sepsis in hospitalized patients
    Hospitalized patients with sepsis who survived to 31 days experienced a 16.2% absolute increase in late mortality.  
  • Most common principal diagnoses for hospitalized patients with HAIs
    The most common principal diagnoses for hospitalized patients with HAIs are: Septicemia 11.8% Adult respiratory failure 5.9% Complications from surgical or medical care 4.1%  
  • HAI Annual Cost
    Healthcare-associated infections in US hospitals cost $96–$147 billion annually.